Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T20921 |
Benazepril
CGS-14824-A,贝那普利 |
||
Benazepril inhibits the activity of circulating angiotensin-converting enzyme (ACE) in horses. | |||
T0180 |
Benazepril hydrochloride
盐酸贝那普利,CGS 14824A HCl,Benazepril HCl,CGS14824A |
RAAS | Endocrinology/Hormones |
Benazepril hydrochloride (CGS 14824A HCl) 是一种血管紧张素转化酶(ACE)抑制剂,能够作用于高血压。 | |||
T71003 |
Infigratinib mesylate
|
||
Infigratinib, also known as, BGJ398 or NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib was approved in 2021 to trea... | |||
T19722 |
Benazeprilat
CGS14831,CGS-14831,CGS 14831 |
RAAS; Endogenous Metabolite | Endocrinology/Hormones; Metabolism |
Benazeprilat(CGS 14831) 是一种具有口服活性的贝那普利活性代谢物。Benazeprilat 具有高效的抗血压活性,可与其他其他类别的化合物(包括噻嗪类利尿剂和钙通道阻滞剂)联合使用来减少与心血管风险和继发性终末器官损伤相关的疾病的发生。Benazeprilat 可能用于研究急性左心室衰竭。 | |||
T71005 |
CGP-42456A
|
||
CGP-42456A - Benazepril Related Compound A, it is an Impurity. Benazepril is a prodrug which is metabolized by the liver into its active form benazeprilat via cleavage of the drug's ester group. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. Benazeprilat has much greater ACE inhibitory activity than does Benazepril. It is indicated for the treatment of hypertension. |